Chart: PARTNER II: Ready To Launch
This article was originally published in The Gray Sheet
Executive Summary
Following well-received one-year results from its PARTNER study, Edwards announced Sept. 23 that it has finally received FDA go-ahead to begin the U.S. pivotal trial of its next-generation Sapien XT transcatheter valve.
You may also be interested in...
FDA OKs Sapien Valve As Pivotal Trial Control Prior To Marketing Approval
Edwards Lifesciences says FDA will support use of the firm's investigational Sapien transcatheter aortic heart valve as a control treatment in an upcoming trial of the firm’s next-generation Sapien XT.
Edwards' Full Euro Launch Of Sapien XT Valve Helps Boost Numbers
The European launch of Edwards Lifesciences' Sapien XT transcatheter valve drove a healthy jump in second-quarter revenue
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.